Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma. Nieto Garcia A, Garriga-Baraut T, Plaza Martin AM, Nieto Cid M, et al. Pediatr Allergy Immunol 2021 Feb 22. doi: 10.1111/pai.13484.

Read + Share

Amedeo Smart

Independent Medical Education

Nieto Garcia A, Garriga-Baraut T, Plaza Martin AM, Nieto Cid M, et al. Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma. Pediatr Allergy Immunol 2021 Feb 22. doi: 10.1111/pai.13484.
PMID: 33619748